Search Results (33)

Objectives: Contrast-enhanced magnetic resonance imaging (CE-MRI) plays an important role in the diagnosis, treatment monitoring, and follow-up of brain tumors. However, the use of gadolinium-based contrast agents (GBCAs) is limited in patients with contraindications, such as severe renal impairment or situations requiring repeated examinations. This study aimed to develop a diffusion model-based Difference-Aware Guided Control Network (DAGCN) for synthesizing high-quality contrast-enhanced T1-weighted MRI (T1-CE) from non-contrast T1-weighted images in combination with an auxiliary sequence. Methods: Using the BraTS 2021 dataset, we proposed a two-stage generative framework that first localizes lesion-related enhancement cues and then guides image synthesis. In the first stage, a Difference-Aware Fusion and Prediction (DAFP) module was designed to extract complementary information from non-contrast T1-weighted images and an auxiliary sequence (T2-weighted or FLAIR) through dual-branch feature extraction and cross-modal channel attention fusion, followed by prediction of a lesion-related discrepancy map. In the second stage, the predicted discrepancy map was concatenated with the original T1-weighted images and introduced into a ControlNet-guided diffusion model to constrain the reverse denoising process and generate the target T1-CE image. Model performance was evaluated by visual comparison, quantitative metrics including peak signal-to-noise ratio (PSNR), structural similarity index measure (SSIM), visual information fidelity (VIF), and normalized cross-correlation (NCC), as well as blinded radiologist scoring of image quality (IQ), clinical replaceability (IC), contrast enhancement (CE), and lesion conformity (CF). Results: DAGCN generated synthetic T1-CE images with preserved global anatomical structure and faithful local lesion enhancement without the need for contrast agent administration. Compared with baseline methods, DAGCN achieved the highest PSNR and NCC under both T1 + T2 and T1 + FLAIR settings, while showing competitive SSIM and VIF performance. Visual comparison and radiologist-based subjective evaluation further indicated improved lesion-focused enhancement fidelity and reduced false-positive enhancement. Among the two auxiliary sequence settings, the T1 + FLAIR configuration provided more specific lesion localization and cleaner background suppression than the T1 + T2 configuration, particularly by reducing interference from cerebrospinal fluid signals. Conclusions: The proposed DAGCN framework enables the synthesis of clinically informative contrast-enhanced-like MRI from non-contrast multi-sequence inputs and may provide a promising alternative for patients in whom gadolinium administration is contraindicated or should be avoided. In particular, the FLAIR-guided setting showed advantages in lesion specificity, background cleanliness, and overall diagnostic quality. Full article

Cross-domain object detection from optical to Synthetic Aperture Radar (SAR) imagery addresses the challenges of SAR data scarcity and high annotation costs, enabling crucial capabilities for persistent maritime surveillance and reconnaissance. However, the substantial modality gap resulting from distinct imaging mechanisms and severe coherent speckle noise significantly hampers knowledge transfer. Existing Unsupervised Domain Adaptation (UDA) methods, which primarily rely on adversarial feature alignment or static pseudo-labeling, struggle to replicate the physical backscattering properties of SAR data and often fall prey to confirmation bias due to intense background clutter. To overcome these limitations, this paper introduces the Diffusion-Enhanced Mutual Consistency (DEMC) framework. DEMC introduces a novel two-stage adaptation paradigm. The first stage, the Diffusion-Based Domain Alignment (DBDA) module, generates a physics-aware intermediate domain. By integrating step-efficient diffusion generation with physical refinement, this module effectively reduces the cross-modal visual discrepancy while preserving the semantic structure of the optical source. In the second stage, this paper tackles the pervasive issue of pseudo-label noise with the Dual-Student Mutual Verification (DSMV) mechanism. Guided by Cross-Agent Spatial Consensus (CASC) and Adaptive Thresholding (AIT), this mechanism dynamically refines pseudo-labels through geometric overlap validation, effectively recovering faint, low-contrast targets that would typically be discarded by standard thresholds. Extensive evaluations across four benchmark tasks (HRSC2016/ShipRSImageNet to SSDD/HRSID) demonstrate that DEMC establishes a new state-of-the-art. Notably, the framework significantly enhances detection recall and reduces omission errors in complex coastal environments, offering a robust solution for zero-tolerance, all-weather surveillance tasks. Full article

As surgery is the first-line paradigm for many solid tumors, precision in preoperative diagnosis and intraoperative imaging is of significant importance. Dual MRI and NIR-II fluorescence imaging could fulfill precision imaging requirements in treating cancers, because of its deep penetration and real-time high spatiotemporal resolution. Thus, the design of dual MRI/NIR-II fluorescence contrast agents is crucial for the diagnosis and surgery of cancers. Herein, we developed optically transparent NaGdF4 matrix-based downshifting nanoparticles (DSNPs) co-doped with Nd³⁺, Yb³⁺, and Er³⁺ as a single nanoplatform for dual NIR-II fluorescence and T1-weighted MRI. Systematic dopant engineering reveals that optimal Nd³⁺ loading enhances cascade Nd → Yb → Er energy transfer and yields intense NIR-II emission at 1334 and 1521 nm upon 808 nm excitation with a relative quantum yield of 1.55, while the presence of Gd³⁺ in the optically transparent matrix imparts strong T1 contrast (4.98 s⁻¹ mM⁻¹). The Pluronic F-127 surface coating confers colloidal stability and biocompatibility. In vitro assays confirm negligible cytotoxicity and efficient cellular uptake. In vivo studies in subcutaneous 4T1 tumor-bearing mice demonstrate robust accumulation, high tumor-to-background contrast in both MRI/NIR-II fluorescence and enable precise NIR-II fluorescence imaging-guided surgery with real-time margin visualization. Therefore, dopant-engineered DSNPs represent a promising dual-modal imaging agent for deep-tissue diagnostic and real-time surgical guidance in precision oncology. Full article

The engineering of theranostic nanoparticles, which integrate diagnostics and therapy in a single administration, enables targeted drug delivery and disease visualization. In cancer theranostics, gadolinium-based nanoparticles are valuable tools for noninvasive magnetic resonance imaging (MRI) and provide high-resolution images of the tumor. When MRI is combined with other imaging modalities, complementary therapeutic information is obtained for more accurate identification of tumor characteristics and precise guidance of anticancer drug delivery. Among the many possible modalities combined with MRI, photoacoustic imaging (PAI) is a candidate that enables sensitive in vivo detection of tumors. We have already succeeded in synthesizing biocompatible gelatin-coated gadolinium oxide nanoparticles with a controlled size by adjusting the timing of gelatin addition, which were a highly efficient contrast agent for MR and PA dual imaging. Herein, we conjugated a clinically used anticancer drug (doxorubicin, DOX) to size-defined and biocompatible gadolinium oxide nanoparticles which are novel theranostic probes. Succinylated gelatin enabled the electrostatic conjugation of DOX with gadolinium oxide nanoparticles, and the release of DOX was controlled through the enzymatic degradation of gelatin by matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9), which are highly expressed in cancer cells. The released DOX efficiently inhibited the growth of HeLa cells in vitro and the growth of the inoculated tumor tissues in vivo. The dual-modality MRI and PAI capabilities provide anatomical information that assists in the localization and targeting of theranostic probes. Full article

Ionizing radiation (IR) exerts complex, dose-dependent biphasic effects on the central nervous system (CNS). This review systematically elucidates the mechanisms underlying the impact of high- and low-dose radiation on neurocognitive function. High-dose radiation (HDR) triggers severe DNA damage, oxidative stress, and neuroinflammatory cascades, leading to neuronal dysfunction, suppression of neurogenesis, and failure of neural circuit reorganization, ultimately resulting in persistent cognitive decline. In contrast, low-dose radiation (LDR) exhibits a unique dual nature: within certain thresholds, it can activate endogenous protective pathways—including DNA repair and antioxidant defenses—thereby promoting neural plasticity and network homeostasis and demonstrating adaptive responses and neuroprotective potential. The research paradigm is shifting from the traditional linear no-threshold (LNT) model towards a dynamic homeostasis model. Future research should prioritize the development of neuroprotective strategies during radiotherapy for high-dose exposure, optimize irradiation modalities, and develop novel radioprotective agents to improve patient outcomes. For LDR, it is crucial to delineate its biological effects and explore its potential for intervening in neurodegenerative diseases. This review aims to provide an integrated theoretical framework for understanding the dose-dependent biphasic regulation of radiation on neurocognition and to outline future directions for developing related protective and therapeutic strategies. Full article

Background/Objectives: Breast cancer (BC) has emerged as a significant threat among female malignancies, resulting in approximately 670,000 fatalities. The capacity to identify BC has advanced over the past two decades because of deep learning (DL), machine learning (ML), and artificial intelligence. The early detection of BC is crucial; yet, conventional diagnostic techniques, including MRI, mammography, and biopsy, are costly, time-intensive, less sensitive, incorrect, and necessitate skilled physicians. This narrative review will examine six novel imaging approaches for BC diagnosis. Methods: Optical coherence tomography (OCT) surpasses existing approaches by providing non-invasive, high-resolution imaging. Raman Spectroscopy (RS) offers detailed chemical and structural insights into cancer tissue that traditional approaches cannot provide. Photoacoustic Imaging (PAI) provides superior optical contrast, exceptional ultrasonic resolution, and profound penetration and visualization capabilities. Hyperspectral Imaging (HSI) acquires spatial and spectral data, facilitating non-invasive tissue classification with superior accuracy compared to grayscale imaging. Contrast-Enhanced Spectral Mammography (CESM) utilizes contrast agents and dual energy to improve the visualization of blood vessels, enhance patient comfort, and surpass standard mammography in sensitivity. Multispectral Imaging (MSI) enhances tissue classification by employing many wavelength bands, resulting in high-dimensional images that surpass the ultrasound approach. The imaging techniques studied in this study are very useful for diagnosing tumors, staging them, and guiding surgery. They are not detrimental to morphological or immunohistochemical analysis, which is the gold standard for diagnosing breast cancer and determining molecular characteristics. Results: These imaging modalities provide enhanced sensitivity, specificity, and diagnostic accuracy. Notwithstanding their considerable potential, the majority of these procedures are not employed in standard clinical practices. Conclusions: Validations, standardization, and large-scale clinical trials are essential for the real-time application of these approaches. The analyzed studies demonstrated that the novel modalities displayed enhanced diagnostic efficacy, with reported sensitivities and specificities often exceeding those of traditional imaging methods. The results indicate that they may assist in early detection and surgical decision-making; however, for widespread adoption, they must be standardized, cost-reduced, and subjected to extensive clinical trials. This study offers a concise summary of each methodology, encompassing the methods and findings, while also addressing the many limits encountered in the imaging techniques and proposing solutions to mitigate these issues for future applications. Full article

Gadolinium-based contrast agents (GBCAs) are the gold standard as MRI probes but are nowadays facing medical limitations and environmental concerns. To address these issues, novel strategies focus on the optimization of Gd(III)-based probes. One promising approach involves incorporating Gd(III) into nanoparticles, particularly coordination polymers, which offer improved relaxivity. In this study, we explore the self-assembly of Gd(III) ions with ascorbate ligand, forming extended coordination polymer architectures. Our investigation focuses on understanding the impact of nanoparticles’ growth and aggregation on their relaxivity properties. Notably, the controlled aggregation process leads to a different distribution of the Gd(III) in the surface and in the bulk of the nanoparticles, mainly responsible for their longitudinal relaxivity. Additionally, the introduction of Eu(III) into the network enables the development of a dual-modal probe with paramagnetic and optical features. Full article

(1) Background: 3D printable materials with accurately defined iodine content enable the development and production of radiological phantoms that simulate human tissues, including lesions after contrast administration in medical imaging with X-rays. These phantoms provide accurate, stable and reproducible models with defined iodine concentrations, and 3D printing allows maximum flexibility and minimal development and production time, allowing the simulation of anatomically correct anthropomorphic replication of lesions and the production of calibration and QA standards in a typical medical research facility. (2) Methods: Standard printing resins were doped with an iodine contrast agent and printed using a consumer 3D printer, both (resins and printer) available from major online marketplaces, to produce printed specimens with iodine contents ranging from 0 to 3.0% by weight, equivalent to 0 to 3.85% elemental iodine per volume, covering the typical levels found in patients. The printed samples were scanned in a micro-CT scanner to measure the properties of the materials in the range of the iodine concentrations used. (3) Results: Both mass density and attenuation show a linear dependence on iodine concentration (R² = 1.00), allowing highly accurate, stable, and predictable results. (4) Conclusions: Standard 3D printing resins can be doped with liquids, avoiding the problem of sedimentation, resulting in perfectly homogeneous prints with accurate dopant content. Iodine contrast agents are perfectly suited to dope resins with appropriate iodine concentrations to radiologically mimic tissues after iodine uptake. In combination with computer-aided design, this can be used to produce printed objects with precisely defined iodine concentrations in the range of up to a few percent of elemental iodine, with high precision and anthropomorphic shapes. Applications include radiographic phantoms for detectability studies and calibration standards in projective X-ray imaging modalities, such as contrast-enhanced dual energy mammography (abbreviated CEDEM, CEDM, TICEM, or CESM depending on the equipment manufacturer), and 3-dimensional modalities like CT, including spectral and dual energy CT (DECT), and breast tomosynthesis. Full article

Background. The diagnosis and treatment of head and neck tumors present significant challenges due to their infiltrative nature and diagnostic hindrances such as the blood–brain barrier. The intricate anatomy of the head and neck region also complicates the clear identification of tumor boundaries and assessment of tumor characteristics. Aim. This review aims to explore the efficacy of molecular imaging techniques that employ targeted contrast agents in head and neck cancer imaging. Head and neck cancer imaging benefits significantly from the combined advantages of CT and MRI. CT excels in providing swift, high-contrast images, enabling the accurate localization of tumors, while MRI offers superior soft tissue resolution, contributing to the detailed evaluation of tumor morphology in this region of the body. Many of these novel contrast agents have integration of dual-modal, triple-modal, or even dual-tissue targeting imaging, which have expanded the horizons of molecular imaging. Emerging contrast agents for the purpose of MRI and CT also include the widely used standards in imaging such as gadolinium and iodine-based agents, respectively, but with peptide, polypeptide, or polymeric functionalizations. Relevance for patients. For patients, the development and use of these targeted contrast agents have potentially significant implications. They benefit from the enhanced accuracy of tumor detection and characterization, which are critical for effective treatment planning. Additionally, these agents offer improved imaging contrast with the added benefit of reduced toxicity and bioaccumulation. The summarization of preclinical nanoparticle research in this review serves as a valuable resource for scientists and students working towards advancing tumor diagnosis and treatment with targeted contrast agents. Full article

Current clinical diagnostic imaging methods for lung metastases are sensitive only to large tumours (1–2 mm cross-sectional diameter), and early detection can dramatically improve treatment. We have previously demonstrated that an antibody-targeted MRI contrast agent based on microparticles of iron oxide (MPIO; 1 μm diameter) enables the imaging of endothelial vascular cell adhesion molecule-1 (VCAM-1). Using a mouse model of lung metastasis, upregulation of endothelial VCAM-1 expression was demonstrated in micrometastasis-associated vessels but not in normal lung tissue, and binding of VCAM-MPIO to these vessels was evident histologically. Owing to the lack of proton MRI signals in the lungs, we modified the VCAM-MPIO to include zirconium-89 (⁸⁹Zr, t_1/2 = 78.4 h) in order to allow the in vivo detection of lung metastases by positron emission tomography (PET). Using this new agent (⁸⁹Zr-DFO-VCAM-MPIO), it was possible to detect the presence of micrometastases within the lung in vivo from ca. 140 μm in diameter. Histological analysis combined with autoradiography confirmed the specific binding of the agent to the VCAM-1 expressing vasculature at the sites of pulmonary micrometastases. By retaining the original VCAM-MPIO as the basis for this new molecular contrast agent, we have created a dual-modality (PET/MRI) agent for the concurrent detection of lung and brain micrometastases. Full article

The combination of multiple imaging methods has made an indelible contribution to the diagnosis, surgical navigation, treatment, and prognostic evaluation of various diseases. Due to the unique advantages of luminogens with aggregation-induced emission (AIE), their progress has been significant in the field of organic fluorescent contrast agents. Herein, this manuscript summarizes the recent advancements in AIE molecules as contrast agents for optical image-based dual/multi-modal imaging. We particularly focus on the exceptional properties of each material and the corresponding application in the diagnosis and treatment of diseases. Full article

The radiolabeled iron oxide nanoparticles constitute an attractive choice to be used as dual-modality contrast agents (DMCAs) in nuclear medical diagnosis, due to their ability to combine the benefits of two imaging modalities, for instance single photon emission computed tomography (SPECT) with magnetic resonance imaging (MRI). Before the use of any DMCA, the investigation of its plasma extra- and on/intra cellular distribution in peripheral human blood is of paramount importance. Here, we focus on the in vitro investigation of the distribution of ^99mTc-DPD-Fe₃O₄ DMCA in donated peripheral human blood (the ligand 2-3-dicarboxypropane-1-1-diphosphonic-acid is denoted as DPD). Initially, we described the experimental methods we performed for the radiosynthesis of the ^99mTc-DPD-Fe₃O₄, the preparation of whole blood and blood plasma samples, and their incubation conditions with ^99mTc-DPD-Fe₃O₄. More importantly, we employed a gamma-camera apparatus for the direct imaging of the ^99mTc-DPD-Fe₃O₄-loaded whole blood and blood plasma samples when subjected to specialized centrifugation protocols. The direct comparison of the gamma-camera data obtained at the exact same samples before and after their centrifugation enabled us to clearly identify the distribution of the ^99mTc-DPD-Fe₃O₄ in the two components, plasma and cells, of peripheral human blood. Full article

In recent decades, magnetic nanoparticles (MNPs) have attracted considerable research interest as versatile substances for various biomedical applications, particularly as contrast agents in magnetic resonance imaging (MRI). Depending on their composition and particle size, most MNPs are either paramagnetic or superparamagnetic. The unique, advanced magnetic properties of MNPs, such as appreciable paramagnetic or strong superparamagnetic moments at room temperature, along with their large surface area, easy surface functionalization, and the ability to offer stronger contrast enhancements in MRI, make them superior to molecular MRI contrast agents. As a result, MNPs are promising candidates for various diagnostic and therapeutic applications. They can function as either positive (T₁) or negative (T₂) MRI contrast agents, producing brighter or darker MR images, respectively. In addition, they can function as dual-modal T₁ and T₂ MRI contrast agents, producing either brighter or darker MR images, depending on the operational mode. It is essential that the MNPs are grafted with hydrophilic and biocompatible ligands to maintain their nontoxicity and colloidal stability in aqueous media. The colloidal stability of MNPs is critical in order to achieve a high-performance MRI function. Most of the MNP-based MRI contrast agents reported in the literature are still in the developmental stage. With continuous progress being made in the detailed scientific research on them, their use in clinical settings may be realized in the future. In this study, we present an overview of the recent developments in the various types of MNP-based MRI contrast agents and their in vivo applications. Full article

During the last decades, the utilization of imaging modalities such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance imaging (MRI) in every day clinical practice has enabled clinicians to diagnose diseases accurately at early stages. Radiolabeled iron oxide nanoparticles (RIONs) combine their intrinsic magnetic behavior with the extrinsic character of the radionuclide additive, so that they constitute a platform of multifaceted physical properties. Thus, at a practical level, RIONs serve as the physical parent of the so-called dual-modality contrast agents (DMCAs) utilized in SPECT/MRI and PET/MRI applications due to their ability to combine, at real time, the high sensitivity of SPECT or PET together with the high spatial resolution of MRI. This review focuses on the synthesis and in vivo investigation of both biodistribution and imaging efficacy of RIONs as potential SPECT/MRI or PET/MRI DMCAs. Full article

Iron oxide nanoparticle (IONPs) have become a subject of interest in various biomedical fields due to their magnetism and biocompatibility. They can be utilized as heat mediators in magnetic hyperthermia (MHT) or as contrast media in magnetic resonance imaging (MRI), and ultrasound (US). In addition, their high drug-loading capacity enabled them to be therapeutic agent transporters for malignancy treatment. Hence, smartening them allows for an intelligent controlled drug release (CDR) and targeted drug delivery (TDD). Smart magnetic nanoparticles (SMNPs) can overcome the impediments faced by classical chemo-treatment strategies, since they can be navigated and release drug via external or internal stimuli. Recently, they have been synchronized with other modalities, e.g., MRI, MHT, US, and for dual/multimodal theranostic applications in a single platform. Herein, we provide an overview of the attributes of MNPs for cancer theranostic application, fabrication procedures, surface coatings, targeting approaches, and recent advancement of SMNPs. Even though MNPs feature numerous privileges over chemotherapy agents, obstacles remain in clinical usage. This review in particular covers the clinical predicaments faced by SMNPs and future research scopes in the field of SMNPs for cancer theranostics. Full article